Objective: To explore β2AR agonist’s effect on PD development with controlling for smoking.

Background: Several studies have suggested the potential protective role of β2-adrenoreceptor agonist (β2AR agonist) on developing Parkinson’s disease (PD). However, those could not reflect a different epidemiologic background in eastern countries. In addition, there have been a small number of studies that controlled the smoking factor.

Method: We used the Korean national sample cohort data (from 2002 to 2013) containing 1,025,340 participants (2.2% of the whole population). The subjects over 60 years were included. PD was defined based on the ICD-10 code, which should be diagnosed by neurologists. Atypical parkinsonisms or ataxic disorders were excluded. We made Set 1 (from 2003 to 2007) and Set 2 (from 2003 to 2008) based on the exposure period for the sensitivity analysis. We observed whether PD had developed during the follow-up periods in each subset.

Results: The PD (Set 1, n=742; Set 2, n=699) and non-PD group (Set 1, n=57645; Set 2, n=66586) were collected. Old age, Medicaid, and asthma were risk factors, whereas smoking was a significant protective factor for PD development. The proportion of β2AR agonist use was significantly higher in the PD group than in the non-PD group (Set 1, 3.6% vs. 2.4%; Set 2, 4.1% vs. 2.6%). β2AR agonist use still was a risk factor in developing PD from the multiple logistic regression analysis.

Conclusion: β2-adrenoreceptor agonist looked like a risk factor rather than a protective factor for PD development. Well-controlled studies reflecting various epidemiologic backgrounds are required to confirm the role of β2AR agonists.
*This study was previously presented at IC-KMDS on December 10^th, 2021.

« Back to 2022 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/a-role-of-%ce%b22-adrenoreceptor-agonist-related-to-the-development-of-parkinsons-disease/